Xiaolong Luo

Xiaolong Luo

Auto-generated profile, based on publicly available information

Xiaolong Luo

Department of Thoracic Surgery, Zhanjiang Central People’s Hospital, Chikan District, Zhanjiang City, Guangdong Province, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2022 in Disease Markers
Verified
Journal Article
Open access
PDF file
HLHong-Ying Liao
Hong-Ying Liao
XLXiaolong Luo
Xiaolong Luo
YHYisheng Huang
Yisheng Huang
XYXingping Yang
Xingping Yang
YZYuzhen Zheng
Yuzhen Zheng
XDXiaofang Deng
Xiaofang Deng
Purpose. DNA methylation heterogeneity is a type of tumor heterogeneity in the tumor microenvironment, but studies on the identification of the molecular heterogeneity of the lung adenocarcinoma genome with respect to DNA methylation sites and their roles in lung cancer progression and prognosis are scarce. Methods. Prognosis-associated DNA methylation subtypes were filtered by the Cox proportional hazards model and then established by unsupervised cluster analysis. Association analysis of these subtypes with clinical features and functional analysis of annotated genes potentially affected by methylation sites were performed. The robustness of the model was further tested by a Bayesian network classifier. Results. Over 7 thousand methylation sites were associated with lung adenocarcinoma prognosis. We identified seven molecular methylation subtypes, including 630 methylation sites. The subtypes yielded the most stable results for differentiating methylation profiles, prognosis, and gene expression patterns. The annotated genes potentially affected by these methylation sites are enriched in biological processes such as morphogenesis and cell adhesion, but their individual impact on the tumor microenvironment and prognosis is multifaceted. Discussion. We revealed that DNA methylation heterogeneity could be clustered and associated with the clinical features and prognosis of lung adenocarcinoma, which could lead to the development of a novel molecular tool for clinical evaluation.